



## NEWS FOR IMMEDIATE RELEASE

### Contact Information:

**Adrienne Choma**  
**President & COO**  
**Saladax Biomedical, Inc.**  
**(201) 240-4072**  
[achoma@saladax.com](mailto:achoma@saladax.com)

### **SALADAX BIOMEDICAL RECEIVES PRODUCT INNOVATION AWARD**

Personalized Chemotherapy Management<sup>®</sup> Tests Are Filling an Unmet Need

**Bethlehem, PA, May 13, 2009-** Saladax Biomedical, developer of the Personalized Chemotherapy Management (PCM<sup>®</sup>) line of tests to measure blood levels of cancer drugs, was pleased to accept the Product Innovation Award from the Ben Franklin Technology Partners of Northeastern Pennsylvania at the i xchange awards ceremony May 12<sup>th</sup>.

Awards were presented in eight categories to companies or individuals who have achieved business success, have helped others to achieve success, or have improved their business through innovation. Saladax was recognized as the company that best demonstrates the commercialization of a unique, innovative product that creatively and effectively meets a market need.

Studies have demonstrated that when chemotherapy drug levels are optimized, treatment can be more efficient and effective, and patients suffer fewer side effects. However, until now oncologists have not had a convenient way of measuring plasma levels, which can vary among individuals as much as 30-fold. As a result, many patients are either over-dosed or under-dosed.

Said company CEO, Dr. Sal Salamone, "I speak for everyone at Saladax when I say that we're pleased to have our work recognized, not least of all because it helps spread the word about a unique new tool with the capacity to dramatically improve care for cancer patients."

#### **About Saladax Biomedical, Inc.**

Saladax Biomedical, Inc. is a personalized diagnostics company with its main R&D and manufacturing facilities based in Bethlehem, PA. Founded in 2004, Saladax is pioneering the development of an innovative line of proprietary Personalized Chemotherapy Management (PCM<sup>®</sup>) assays to test plasma levels of the most commonly used anti-cancer medicines. In the European Union, Saladax is marketing its 5-FU PCM Assay directly and has obtained a CE Mark for product distribution.

For more information about Saladax, visit [www.saladax.com](http://www.saladax.com).